8
Evaluation and Diagnosis
Patient population
LDL-C <100 mg/dL (2.6 mmol/L)
Non–HDL-C <130 mg/dL (3.4 mmol/L)
Primary prevention PREVENT-ASCVD <10%
• If TG ≥150 mg/dL to 499 mg/dL,
apoB goal: <90 mg/dL
Severe
hypercholesterolemia
Without FH, ASCVD risk factors, and
subclinical atherosclerosis
Diabetes Without ASCVD risk factors or
diabetes-specific risk modifiers
• apoB goal: <90 mg/dL
Subclinical
atherosclerosis
CAC = 1–99 AU and <75th percentile
for age, sex, and race
Hypertriglyceridemia <50 y old with no additional risk enhancers
Clinical ASCVD N/A
Figure 1. Lipoprotein Goals for ASCVD Risk Reduction
apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; AU,
Agatston units; CAC, coronary artery calcium; CKD, chronic kidney disease; FH, familial
hypercholesterolemia; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density
lipoprotein-cholesterol; and TG, triglycerides.
